D.C. Mun. Regs. tit. 22, r. 22-B215

Current through Register Vol. 71, No. 49, December 6, 2024

Rule 22-B215 - MONITORING AND REPORTING THE OCCURRENCE OF CANCER

215.1

Each health care provider and health care facility shall report benign tumors of the brain and central nervous system and all malignant cancers as follows:

(a) Each health care provider and health care facility shall report within six (6) months of diagnosis or first contact, any patient diagnosed with or treated for benign tumors of the brain or central nervous system or any malignant cancers, or for whom cancer treatment planning was performed but the patient opted for no treatment.

(b) Each health care provider and health care facility shall report within six (6) months of diagnosis or first contact, any patient diagnosed with or treated for benign tumors of the brain or central nervous system or any malignant cancers, or who expired with cancer as a cause of death; and

(c) Each health care provider and health care facility shall make available to the Director or an agent of the Director all information necessary to verify the information in any report submitted pursuant to this section.

215.2

The information required to be submitted by this section may be submitted by the health care facility, health care provider, or an agent retained by the health care facility or health care provider for this purpose.

215.3

Each report of an initial diagnosis or the treatment of cancer shall include the following:

(a) Patient Information:

(1) Name, including maiden name, if applicable;

(2) Legal residence and mailing address at the time of initial diagnosis;

(3) Sex;

(4) Social security number;

(5) Date of birth;

(6) Place of birth;

(7) Race or ethnic group; and

(8) Marital status; and

(b) Diagnostic Information:

(1) Diagnosis;

(2) Histologic type, behavior and grade of cancer;

(3) Primary site of the cancer;

(4) Date of the diagnosis;

(5) Extent of disease, including the American Joint Commission on Cancer (AJCC) stage and the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) stage;

(6) Type of diagnosis and confirmation;

(7) Laterality;

(8) Tissue pathology;

(9) Initial treatment, including surgery, radiation, chemotherapy, hormonal therapy, or biological therapy; and

(10) Sequence of the cancer; and

(c) Other Information:

(1) Name of the health care facility or health care facility provider;

(2) Patient's medical record number;

(3) Name of the attending physician;

(4) Name of the person submitting the report;

(5) Patient's history of tobacco use (current, former, or never);

(6) Patient's current, former, and usual occupational status; and

(7) Any other information considered pertinent by the Director.

215.4

Each report required by Subsection 215.1 shall be submitted electronically by a secured form of transmission approved by the North American Association of Central Cancer Registries (NAACCR) to the DC Central Cancer Registry within the Department.

D.C. Mun. Regs. tit. 22, r. 22-B215

Final Rulemaking published at 47 DCR 3493 (May 19, 2000); as amended by Final Rulemaking published at 61 DCR 4939 (May 16, 2014)

Authority: Section 2(a) of the Preventive Health Services Amendments Act of 1985 ("Act"), effective February 21, 1986 (D.C. Law 6-83; D.C. Official Code § 7-301 (2012 Repl.)), and Mayor's Order 98-141, dated August 20, 1998.